Cytokinetics, Inc. (NASDAQ:CYTK) Insider Purchases $3,311,256.96 in Stock
Cytokinetics, Inc. (NASDAQ:CYTK) insider Value Fund L. P. Biotechnology acquired 342,072 shares of Cytokinetics stock in a transaction on Wednesday, December 11th. The stock was purchased at an average cost of $9.68 per share, with a total value of $3,311,256.96.
CYTK stock opened at $9.68 on Friday. Cytokinetics, Inc. has a twelve month low of $5.75 and a twelve month high of $14.94. The company has a quick ratio of 8.20, a current ratio of 8.20 and a debt-to-equity ratio of 12.35. The stock’s 50 day moving average is $9.78 and its 200-day moving average is $11.33. The firm has a market capitalization of $561.87 million, a PE ratio of -4.96 and a beta of 1.40.
Cytokinetics (NASDAQ:CYTK) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.06. Cytokinetics had a negative return on equity of 10,351.99% and a negative net margin of 378.70%. The company had revenue of $6.06 million for the quarter, compared to analyst estimates of $7.80 million. On average, equities research analysts anticipate that Cytokinetics, Inc. will post -2.02 earnings per share for the current fiscal year.
A number of brokerages have commented on CYTK. JMP Securities set a $23.00 price objective on Cytokinetics and gave the company a “buy” rating in a research note on Friday, September 13th. ValuEngine cut Cytokinetics from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. BidaskClub raised Cytokinetics from a “sell” rating to a “hold” rating in a research note on Thursday, November 21st. Piper Jaffray Companies restated an “overweight” rating and issued a $20.00 target price (up previously from $14.00) on shares of Cytokinetics in a report on Monday, September 16th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 target price (up previously from $14.00) on shares of Cytokinetics in a report on Friday, September 6th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $19.86.
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.
Featured Story: Asset Allocation
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.